Related Experiment Video
Updated: Oct 27, 2026

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Chromophobe renal cell carcinoma: addressing the translational gap toward precision oncology for advanced disease
Xiwen Lei1, Rui Dong2, Lijuan Yin1
1Department of Pathology, Changhai Hospital, Naval Medical University, 168 Changhai Rd. Building 17, Room 708, Shanghai, 200433, China.
Background:
Chromophobe renal cell carcinoma (chRCC) represents a distinct histological subtype of kidney cancer. While typically characterized by an indolent clinical course, it presents significant management challenges in advanced or late-stage disease. This review presents current evidence regarding chRCC histopathology, emerging biomarkers, and proposed grading systems. We comprehensively analyze the molecular landscape, highlighting TP53 and PTEN mutations alongside characteristic chromosomal losses, while evaluating the role of epigenetic modifications and the immune microenvironment. Crucially, the paper details the mechanisms through which mitochondrial dysfunction and metabolic reprogramming drive chRCC pathogenesis. By assessing contemporary clinical trials, this work underscores the necessity for novel therapeutic interventions and the collection of large-scale prospective data to address current gaps in treatment.
Conclusion:
A precision oncology framework for chRCC should prioritize reproducible diagnosis, cautious biomarker validation, and prospective rare-tumor trials to refine risk stratification and management.
More Related Videos
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
05:36Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer